Akums Drugs and Pharmaceuticals · NSE: AKUMS · BSE: 544222
Q1 FY27 results · Apr–Jun 2026
Akums Drugs and Pharmaceuticals reported revenue from operations of ₹1,166.63 crore (up 13.9% from Q1 FY26) and net profit of ₹100.98 crore (up 56.1% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,166.63 | 1,024.03 | +13.9% | 1,157.87 | +0.8% |
| Other income | 30.38 | 26.73 | +13.7% | 35.30 | −13.9% |
| Total income | 1,197.01 | 1,050.76 | +13.9% | 1,193.17 | +0.3% |
| Profit before tax | 139.24 | 95.65 | +45.6% | 121.22 | +14.9% |
| Net profit for the period | 100.98 | 64.69 | +56.1% | 81.34 | +24.1% |
| Attributable to shareholders of the company | 100.01 | 63.48 | +57.6% | 84.61 | +18.2% |
| EPS, basic (₹) | 6.53 | 4.15 | +57.3% | 5.53 | +18.1% |
| Net margin (%) | 8.7 | 6.3 | 7.0 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 392.27 | 332.44 | +18.0% | 338.37 | +15.9% |
| Other income | 26.10 | 28.55 | −8.6% | 27.73 | −5.9% |
| Total income | 418.38 | 361.00 | +15.9% | 366.10 | +14.3% |
| Profit before tax | 59.34 | 59.51 | −0.3% | 21.79 | +172.3% |
| Net profit for the period | 44.84 | 44.87 | −0.1% | 15.20 | +195.1% |
| EPS, basic (₹) | 2.93 | 2.93 | +0.0% | 0.99 | +196.0% |
| Net margin (%) | 11.4 | 13.5 | 4.5 |
Consolidated
- Filed with BSE
- 08 Aug 2026, 18:01 IST
- Board meeting
- 08 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Aug 2026, 18:01 IST
- Board meeting
- 08 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE